Help Improve Patient Compliance with Cancer Screening

Take the first step to address patient cancer risk before they leave your office

Did you know that as many as 25% of patients fail to adhere to their doctor’s treatment recommendations? Patients’ non-adherence to physician recommendations for cancer screenings puts lives in jeopardy since cancers found in later stages are harder to cure.

MyCancerRisk™ is a program offered by Innovative Diagnostic Laboratory to help improve patient adherence to cancer screening through convenient blood-based, cancer risk assessment tests that can be performed at the same time as a routine blood draw. Unlike other tests that identify cancer in its later stages, our tests can help identify early cancer indicators that give physicians the information they need to encourage patients to comply with national screening guidelines. Test results come with educational materials to help create teachable moments between physicians and patients.

Our three step program helps physicians:

1. Identify a patient’s individual cancer risk through convenient tests you can initiate right in your own office.
2. Communicate the results to patients and help them understand their individual risk for certain types of cancers.
3. Address patient risk by encouraging further screenings and the adoption of healthier habits.

8751 Park Central Drive, Suite 200
Richmond, VA 23227
How do I get started?
Contact us and you’ll receive:

- Brochures, patient risk assessment forms and posters to educate patients and encourage dialogue between you and your patients.
- Easy instructions and helpful assistance for ordering test supplies for your practice.
- Training on how to read and interpret test results.

Call customer service today to get started
1.855.420.7140

About our tests

ColonSentry® can help you and your patients decide if further diagnostic procedures are right for them.

When a lecture isn’t enough, using EarlyCDT® Lung may help spark a change in high risk patients.

PHI has been demonstrated to have higher specificity than PSA alone.

The ColonSentry® test measures the expression of seven gene biomarkers that are indicators of colorectal cancer. The ColonSentry® blood test can be incorporated into a routine blood draw to encourage at risk patients to be screened for colorectal cancer.

EarlyCDT®-Lung measures seven autoantibodies in the blood that serve as early indicators of lung cancer. EarlyCDT®-Lung can help physicians assess high risk, asymptomatic patients and can help detect lung cancers before they are visible by CT.\(^1,2\)

\(\textit{phi}\) is a blood test that is up to 3 times more specific than PSA and percent free PSA alone. \(\textit{phi}\) can help differentiate prostate cancer from benign conditions and therefore reduce unnecessary biopsies. \(^3,4,5\)

Visit [www.myinnovativelab.com](http://www.myinnovativelab.com) for more information
call 1.855.420.7140 or email customerservice@myinnovativelab.com

---


\(\ast\) At 90 percent clinical sensitivity.